Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
153
days
Evolution of the global emergency vaccine stockpile system
AuthorsJenny A. Walldorf; Jaymin C. Patel; Laurence Cibrelus; Katya Fernandez; Malika Bouhenia; Vachagan Harutyunyan; Lorenzo Pezzoli; J. Erin Staples; Tim Nguyen; Alejandro Costa
Affiliations1. Centers for Disease Control and Prevention, Global Health Center; 2. World Health Organization; 3. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases
277
days
United States healthcare providers’ views on pediatric meningococcal disease and vaccination
AuthorsOscar Herrera-Restrepo; Vasudha Gupta; Sophie Jacobovitz; Tosin Olaiya; Elise Kuylen; Karam Dahyaleh; Kristin K. Johnson; Thatiana Pinto; Sofia B. Pinto; Jana Shaw
Affiliations1. GSK, Philadelphia, PA, USA; 2. IQVIA, Durham, NC, USA; 3. GSK, Wavre, Belgium; 4. GSK, Rio de Janeiro, Brazil; 5. SUNY Upstate University Hospital, Syracuse, NY, USA
118
days
Narrative review of the clinical safety of MenACYW-TT: a quadrivalent meningococcal vaccine conjugated to tetanus toxoid licensed in the US and abroad
AuthorsOlga Syrkina; Mary Bausch-Jurken; Arlette Delgado; Jelena Jovanovic; Corwin A. Robertson
Affiliations1. Sanofi; 2. IQVIA
77
days
Stroke risk following BNT162b2 vaccination: a systematic review and meta-analysis of self-controlled case series studies
AuthorsSeol Jang; Sung-Inn Pyo; Eun Jin Kim; Woojoo Lee; Soon-Sun Kwon
Affiliations1. Ajou University; 2. Ajou University School of Medicine; 3. Seoul National University
123
days
Association between influenza vaccination and severe outcomes in adults aged ≥ 65 years hospitalized with laboratory-confirmed influenza: a retrospective cohort study, I-MOVE hospital network, Europe, 2015/16–2024/25
AuthorsDiogo F. P. Marques; Angela M. C. Rose; Susana Monge; Iván Martínez-Baz; Marijke Reynders; Róisín Duffy; Sierk D. Marbus; Silvia Bino; Petr Husa; Ralf Dürrwald; Liem Binh Luong Nguyen; Goranka Petrović; Beatrix Oroszi; Antonino Bella; Monika Kuliese; Stephen Abela; Iwona Paradowska-Stankiewicz; Ausenda Machado; Odette Popovici; Chris Robertson; Francisco Pozo; Ana S. Lameiras Azevedo; Camino Trobajo-Sanmartín; Anna Parys; Lisa Domegan; Arianne B. van Gageldonk-Lafeber; Lenka Součková; Kristin Tolksdorf; Odile Launay; Vesna Višekruna Vučina; Gergő Túri; Flavia Riccardo; Ligita Jančorienė; John Paul Cauchi; Verónica Gómez; Mihaela Lazar; Jim McMenamin; Baltazar Nunes
Affiliations1. Epidemiology Department, Epiconcept; 2. NOVA University Lisbon; 3. Carlos III Health Institute (CNE-ISCIII); 4. Consortium for Biomedical Research in Infectious Diseases (CIBERINFEC); 5. Instituto de Salud Pública de Navarra – IdiSNA – CIBERESP; 6. Algemeen Ziekenhuis Sint-Jan; 7. Health Service Executive-Health Protection Surveillance Centre (HSE-HPSC); 8. National Institute for Public Health and the Environment; 9. Control of Infectious Diseases Department, Institute of Public Health; 10. University Hospital Brno, Masaryk University; 11. Robert Koch Institute; 12. Université de Paris Cité; 13. INSERM, I-REIVAC Network, Paris, France; 14. CIC 1417, AP-HP, Hôpital Cochin, Paris, France; 15. Croatian Institute of Public Health; 16. Semmelweis University; 17. Istituto Superiore di Sanità; 18. Lithuanian University of Health Sciences; 19. Health Promotion and Disease Prevention; 20. National Institute of Public Health National Institute of Hygiene – National Research Institute; 21. National Institute of Health Doctor Ricardo Jorge; 22. National Centre for Surveillance and Control of Communicable Diseases, National Institute of Public Health Bucharest; 23. Clinical and Protecting Health Directorate, Public Health Scotland; 24. University of Strathclyde; 25. Institute of Health Carlos III; 26. Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP); 27. Directorate-General of Public Health; 28. National Influenza Centre, Sciensano; 29. Vilnius University; 30. Queen Mary University of London; 31. National Institute of Research and Development for Microbiology and Immunology“Cantacuzino”; 32. University of Glasgow
272
days
Comparison of immunogenicity, safety, and efficacy of EVA71 vaccine in children: a systematic review and meta-analysis
AuthorsMuhammad Gilang Dwi Putra; Rodman Tarigan Girsang; Rais Amaral Haq; Teuku Fais Duta; Frengki Prabowo Saputro Wijayanto; Artha Maressa Theodora Simanjuntak; Eddy Fadlyana; Kusnandi Rusmil
Affiliations1. Faculty of Medicine Universitas Padjadjaran; 2. Universitas Lampung; 3. Universitas Syiah Kuala; 4. Gadjah Mada University
93
days
Priority setting for older adult vaccines in Indonesia: a multi-criteria decision analysis using SMART vaccines
AuthorsMohammed Alfaqeeh; Neily Zakiyah; Maarten J. Postma; Anas Hamad; Auliya A. Suwantika
Affiliations1. Universitas Padjadjaran; 2. University Medical Center Groningen, University of Groningen; 3. University of Groningen; 4. Hamad Medical Corporation; 5. Qatar University
212
days
Cohort studies may underestimate rare vaccine adverse events: evidence from stroke incidence following COVID-19 vaccination
AuthorsHiam Chemaitelly; Naveed Akhtar; Salman Al Jerdi; Saadat Kamran; Sujatha Joseph; Deborah Morgan; Ryan Uy; Fatma B. Abid; Abdullatif Al-Khal; Abdul-Badi Abou-Samra; Adeel A. Butt; Laith J. Abu-Raddad
Affiliations1. Cornell University; 2. Hamad Medical Corporation; 3. Qatar University; 4. University of Toledo; 5. Hackensack Meridian Health Network JFK University Medical Center; 6. Hamad Bin Khalifa University
68
days
Harnessing trained immunity for next-generation vaccines: from rational adjuvant design to self-adjuvanting antigens
AuthorsJing Wang; Xiao-Yong Fan; Zhidong Hu
Affiliations1. Fudan University
25
days
Rational design of M2e-based nanoparticle vaccines for universal influenza a protection
AuthorsLouis Bourlon; Jessica Morlieras; Patrice N. Marche; Fabrice P. Navarro
Affiliations1. Sanofi Pasteur; 2. Univ. Grenoble Alpes
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days